MultiVir Clinical Trials Information

Tumor suppressor p53 and IL24 gene abnormalities are among the most common molecular defects in cancers causing tumor progression, treatment resistance and immune suppression.

MultiVir’s Ad-p53 and Ad-IL24 product candidates deliver normal p53 and IL24 genes into tumors to restore their tumor suppressor functions which include inhibition of tumor growth and the activation of anti-tumor immune responses.

The Ad-p53 Dendritic Cell Vaccine (Ad-p53 DCV) is an investigational immune stimulating therapy designed to activate the immune system to attack tumor cells that express high levels of p53 which occurs in many types of cancer.

Active Clinical Trials

Planned Clinical Trials

Active Clinical Trials

Head-and-Neck

Liver-metases

Liver-metases

Planned Clinical Trials

Melanoma